The stakes of that question are enormous because the HER2 axis was redrawn only recently. For decades, pathologists sorted breast tumors into a binary: those that amplified the human epidermal growth factor receptor 2 and those that did not. Then came the recognition of HER2-low disease, tumors that stain weakly positive for the protein on immunohistochemistry without gene amplification. The arrival of trastuzumab deruxtecan, an antibody-drug conjugate that showed striking activity in HER2-low advanced breast cancer, transformed this once-incidental staining pattern into a therapeutically meaningful category. Suddenly, the difference between an IHC score of 0 and 1+ could determine whether a patient received an entirely new class of drug.

In the study, the researchers classified patients as HER2-0, HER2-low, or HER2-positive and examined three outcomes: the metastasis-free interval, the first site of metastasis, and survival after metastatic diagnosis. The cohort was strikingly balanced at the low end of the HER2 spectrum. Some 647 patients, or 40.5 percent, had HER2-0 tumors, while 672, or 42 percent, had HER2-low tumors; the remaining 280 patients, 17.5 percent, had HER2-positive disease. Using chi-square tests, Welch one-way ANOVA, Kaplan-Meier estimation, and binary, ordinal logistic, and Cox regression models, the team compared outcomes across the three groups with and without adjustment for other clinical factors.

The first major finding concerned timing. HER2-positive tumors metastasized earliest, with a median metastasis-free interval of 2.7 years, compared with 3.3 years for HER2-low and 3.7 years for HER2-0 tumors, a difference that reached statistical significance at p = 0.002. When the researchers modeled the odds of late recurrence, defined as metastasis occurring five or more years after diagnosis, HER2-positive tumors carried markedly lower odds of late spread than HER2-0 tumors, with an odds ratio of 0.39 and a 95 percent confidence interval of 0.22 to 0.68. In other words, tumors that overexpress HER2 behave biologically like accelerants, seeding distant organs sooner after the original diagnosis.

By contrast, HER2-low tumors and HER2-0 tumors were statistically indistinguishable in metastatic timing. The median intervals of 3.3 and 3.7 years did not separate into distinct biologic rhythms once the data were examined carefully. This finding cuts against the hope, implicit in some earlier work, that low-level HER2 expression might mark a subtly different disease course in the interval between primary diagnosis and metastatic relapse. On the clock of metastasis, at least, HER2-low disease appears to run on the same schedule as HER2-0 disease.

The second question, where the cancer spreads first, produced a nuanced answer. In unadjusted analyses, the first metastatic site did differ across the HER2 groups, hinting that the biology of the three categories might shape organotropism, the tendency of cancer cells to colonize particular organs. But when the researchers adjusted for other clinical variables in binary logistic regression models, HER2 status was no longer independently associated with either bone-only or central nervous system-only presentations. The apparent differences in spread patterns, the analysis suggests, may reflect the company that HER2 status keeps, including hormone receptor status and other tumor characteristics, rather than a metastatic program driven by HER2 expression level itself.

Survival told a different and more hopeful story. In adjusted Cox regression models, both HER2-low and HER2-positive disease were associated with a lower hazard of death compared with HER2-0 disease. Patients with HER2-low tumors had a 15 percent reduction in the hazard of death, with a hazard ratio of 0.85 and a confidence interval of 0.74 to 0.97. Patients with HER2-positive tumors fared better still, with a 27 percent reduction in hazard, a hazard ratio of 0.73, and a confidence interval of 0.60 to 0.88. The paradox is notable: HER2-positive disease recurs earliest yet kills slowest after recurrence, a pattern the authors attribute in part to the extraordinary armamentarium of HER2-targeted therapies, from trastuzumab and pertuzumab to antibody-drug conjugates, that have reshaped the natural history of HER2-amplified metastatic disease.

The modest survival advantage of HER2-low disease over HER2-0 disease is harder to explain. The study was not designed to dissect mechanisms, but several candidates merit attention. Hormone receptor status, which strongly influences both prognosis and treatment options, may partly account for the difference, since HER2-low status is more common among hormone receptor-positive tumors. Differences in treatment exposure, including increasing use of antibody-drug conjugates in patients whose tumors express even low levels of HER2, may also contribute in more recent cohorts. Or the finding could reflect residual confounding that adjustment could not fully remove. The authors are appropriately measured: they conclude that HER2-low status is useful for outcome stratification but may not independently define a distinct metastatic phenotype.

The clinical implications ripple outward from that conclusion. The results reinforce the idea that HER2-low is best understood as a treatment-predictive biomarker rather than a wholly distinct biologic subtype. For patients whose tumors are HER2-low, the metastatic course, in timing and in pattern of spread, will look much like that of HER2-0 disease, and counseling and surveillance strategies need not differ on those grounds. Yet the observed survival difference suggests that HER2-low status still carries prognostic information, and the availability of trastuzumab deruxtecan means that accurate, guideline-concordant HER2 testing at both ends of the spectrum is more consequential than ever. The ASCO and College of American Pathologists guideline updates on HER2 testing have emphasized exactly this point: precision at the low end of the scale now changes therapy.

For researchers, the study opens as many questions as it closes. If HER2-low disease does not differ in metastatic timing or adjusted pattern of spread, what accounts for its post-metastatic survival edge, and is that edge shrinking or growing as antibody-drug conjugates enter earlier lines of therapy? Would prospective cohorts with central HER2 testing, genomic characterization of the kind performed in recent HER2-low versus HER2-0 genomic studies, and contemporary treatment data confirm these retrospective signals? The study was approved by the University of Pittsburgh Institutional Review Board and received no specific funding, and its authors, led by Ali Sanjari Moghaddam with corresponding author Margaret Q. Rosenzweig, note that patient-level data remain restricted but may be shared upon reasonable request. What the work delivers now is a clear-eyed baseline: in the metastatic setting, the HER2-low category earns its place in clinical decision-making not by redrawing the map of how breast cancer spreads, but by modestly rewriting its ending.

Subject of Research: Comparative metastatic behavior and post-metastatic survival across HER2-0, HER2-low, and HER2-positive metastatic breast cancer

Article Title: Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer

Article References: Sanjari Moghaddam, A., Deng, Z., Sereika, S. M., Habib, M., Homeniuk, A., Brufsky, A. M., & Rosenzweig, M. Q. (2026). Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer. Breast Cancer Research and Treatment, 219(3), Article 11. https://doi.org/10.1007/s10549-026-08067-4

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08067-4

Keywords: HER2-low breast cancer, HER2-0 breast cancer, HER2-positive breast cancer, metastatic breast cancer, metastasis-free interval, post-metastatic survival, first metastatic site, trastuzumab deruxtecan, biomarker stratification, hormone receptor status, breast cancer prognosis, oncology

Hormone-receptor-negative breast cancer—most of it triple-negative, meaning the tumor lacks estrogen receptors, progesterone receptors and surplus HER2—is among the most lethal common subtypes of the disease. It disproportionately strikes younger women and carriers of BRCA1 mutations, grows quickly, and metastasizes early. Once it reaches distant organs, survival is measured in a few years at best, and historically it was counted in months. Recent gains have been incremental at best. Platinum salts and taxanes remain the chemotherapy backbone, and pembrolizumab added to chemotherapy extends life chiefly in the minority of patients whose tumors express the PD-L1 protein at high levels—a biomarker found in fewer than half of metastatic cases. For everyone else, checkpoint inhibitors have offered little. Adding to the challenge, pathologists now recognize that a large share of these apparently HER2-negative tumors are not truly negative: they carry low levels of the HER2 protein on the cell surface, visible as faint immunohistochemical staining, a state the field has termed HER2-low.

HER2-low is defined as cancer scored 1+ on immunohistochemistry, or 2+ with no gene amplification on in situ hybridization—receptor levels once dismissed as biologically irrelevant. Trastuzumab deruxtecan, developed by Daiichi Sankyo and AstraZeneca, changed that view. The drug consists of a trastuzumab antibody tethered through an enzyme-cleavable tetrapeptide linker to deruxtecan, a potent inhibitor of topoisomerase I, an enzyme that dividing cells need to untangle DNA during replication. With roughly eight payload molecules riding on each antibody—a drug-to-antibody ratio far higher than earlier conjugates achieved—the drug delivers a concentrated chemotherapy dose directly to HER2-expressing cells. After the antibody binds its target and is engulfed into the lysosome, tumor-cell enzymes clip the linker, releasing the payload to poison DNA replication. Critically, the released drug is membrane-permeable, so it diffuses into neighboring tumor cells that express little or no HER2. This bystander effect explains why the conjugate works at receptor densities once considered far too low to target, and in earlier randomized studies it roughly doubled progression-free survival compared with standard chemotherapy in pretreated patients with HER2-low metastatic disease.

Durvalumab attacks the tumor from a different direction. The monoclonal antibody binds PD-L1, the molecular brake that tumors and immune cells deploy to shut down cytotoxic T lymphocytes, releasing those cells to resume their attack. The logic for combining it with trastuzumab deruxtecan rests on a decade of tumor immunology showing that antibody-drug conjugates do far more than kill their targets. The DNA damage inflicted by topoisomerase I inhibition can activate the cGAS–STING pathway, the cell’s alarm sensor for misplaced DNA, triggering type I interferon release. Dying tumor cells spill antigens that dendritic cells carry to lymph nodes for T-cell priming, while stressed tumor cells raise the density of MHC class I molecules and PD-L1 on their surface. In laboratory models, topoisomerase I inhibitors effectively behave as an in situ vaccine, converting immunologically cold tumors into inflamed ones that checkpoint inhibitors can exploit. The question BEGONIA posed was whether this mechanistic synergy would hold in human breast cancer, in women receiving both agents as their first treatment for advanced disease.

BEGONIA was conceived as a platform study rather than a single comparison: multiple parallel arms tested durvalumab alongside different investigational partners, including antibodies against CD73 and NKG2A, a STAT3-targeting antisense oligonucleotide, and trastuzumab deruxtecan. The design allowed several drug combinations to be evaluated simultaneously under shared infrastructure, with each arm reporting once it accrued enough patients. The arm reported in Nature Cancer enrolled women with locally advanced, unresectable or metastatic hormone-receptor-negative breast cancer whose tumors were HER2-low and who had not yet received drug therapy for advanced disease. Patients received both agents at established doses on three-week cycles, continuing until their disease progressed or toxicity became unacceptable. Because the study was open-label and lacked a randomized control group, its primary endpoint was the objective response rate—the proportion of patients whose tumors shrank by at least 30 percent, as confirmed by blinded independent central review—together with duration of response, progression-free survival and safety. Enrollment spanned cancer centers across Europe, Asia and North America, capturing the heterogeneity of real-world clinical populations.

The efficacy signals exceeded what either drug’s record alone would predict. Around 62 percent of patients achieved a confirmed objective response, and a small subset saw all detectable disease disappear—complete responses that are rare with conventional first-line chemotherapy in this setting. The median duration of response had not been reached when the data were locked, with the majority of responses still ongoing at analysis and many patients remaining on treatment beyond a year. Notably, responses appeared across the cohort irrespective of tumor PD-L1 expression, hinting that the combination might reach patients who historically derive little benefit from checkpoint inhibition. Disease control—tumors that shrank or remained stable—encompassed the large majority of treated patients. Whether that translates into longer survival will require longer follow-up, but the depth and persistence of the early responses is precisely what caught researchers’ attention in a disease where first-line chemotherapy shrinks tumors in only about a third of cases.

The safety profile combined the known liabilities of both drugs. Toxicities consistent with trastuzumab deruxtecan—nausea, fatigue, hair loss and myelosuppression, particularly anemia and neutropenia—were common, and roughly half of patients experienced grade 3 or worse treatment-related events that required dose interruption or reduction. Durvalumab contributed immune-mediated effects such as thyroid dysfunction and liver enzyme elevations. The toxicity demanding the most vigilance was interstitial lung disease, the inflammatory lung injury recognized as a class effect of trastuzumab deruxtecan across its development program. It occurred in only a small fraction of patients, predominantly at low grade, and was managed with treatment interruption and corticosteroids. No unexpected safety signals emerged, the investigators report, and the pattern of events matched what had been seen when each drug was used alone. Yet because durvalumab can itself provoke pneumonitis, the overlap of two lung-toxicity risks made pulmonary monitoring a central element of the protocol, with clinicians urged to suspect drug-related lung injury in any new respiratory symptom and to treat it early.

The trial was led by Peter Schmid of Queen Mary University of London, with Se Hyun Im of Asan Medical Center in Seoul and Zbigniew Nowecki of the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw among the senior investigators. Writing in Nature Cancer, the authors describe response rates that compare favorably with historical benchmarks for first-line therapy in hormone-receptor-negative, HER2-low disease, and argue that the pairing’s activity independent of PD-L1 status addresses one of immunotherapy’s persistent blind spots in this subtype. They are careful, however, to frame the study as hypothesis-generating. With a single-arm design and no randomized comparator, the results establish feasibility, response depth and tolerability, but not survival advantage. The authors call for the regimen to be advanced into randomized phase III testing, where durvalumab plus trastuzumab deruxtecan would be measured head-to-head against the current standards of pembrolizumab with chemotherapy and chemotherapy alone.

The results arrive at a moment when the logic of breast cancer sequencing is being rewritten. Trastuzumab deruxtecan is already approved for HER2-low metastatic disease, but only after patients have progressed on earlier lines of therapy; its position has been in the back half of the treatment journey. Moving the drug to the front line, and pairing it with an immunotherapy, raises immediate questions. Do patients who receive the conjugate early forfeit its later benefit if the disease eventually progresses, or does earlier exposure translate into longer survival? How should clinicians handle tumors that are HER2-ultralow, expressing the protein at even fainter levels that current tests barely register? And does the HER2-low label, which depends on subjective immunohistochemistry scoring, reliably identify the right patients when the stakes are a front-line regimen? The HER2-low population is also biologically heterogeneous, mixing immunologically inflamed tumors with cold ones, and translational analyses from BEGONIA are expected to clarify which microenvironments the combination actually reprograms.

For now, the findings stand as a proof of principle: a targeted chemotherapy payload and an immune checkpoint inhibitor can be combined safely and effectively as an initial treatment in one of breast cancer’s most difficult molecular neighborhoods. If randomized trials confirm the kind of survival gains that single-arm data cannot demonstrate, the first-line landscape for hormone-receptor-negative, HER2-low metastatic disease could shift away from cytotoxic chemotherapy toward regimens that couple precision targeting with immune activation—a strategy oncologists have pursued across solid tumors for a decade. The necessary next step—randomized confirmation—will determine whether regulators follow where the biology points. With survival in this population still measured in only a few years, and breast cancer remaining the leading cause of cancer death in women worldwide, the stakes are considerable. The BEGONIA results suggest the tools to change that arithmetic may already be in hand; what remains is to prove, in the rigorous language of randomized evidence, that the promise holds.